canakinumab
Novartis
['biomarker', 'canakinumab', 'marker ']
other canakinumab studies pending full analysis and biomarker data to come but disappointing results overall. did the cantos data support exploration in these very different clinical settings? #esmo22 
Director of Thoracic Oncology & Developmental Therapeutics @LombardiCancer, Associate Professor @Georgetown University #LCSM #HereWeGo #ITYSL He/Him